Shifting the Focus: The Primary Role of IL-23 in Psoriasis and other Inflammatory Disorders.

about

Shifting the Focus: The Primary Role of IL-23 in Psoriasis and other Inflammatory Disorders.

Item

http://www.wikidata.org/entity/Q50041283

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Shifting the Focus: The Primar ...... other Inflammatory Disorders.

@en

Shifting the Focus: The Primar ...... other Inflammatory Disorders.

@nl

type

Item

label

Shifting the Focus: The Primar ...... other Inflammatory Disorders.

@en

Shifting the Focus: The Primar ...... other Inflammatory Disorders.

@nl

prefLabel

Shifting the Focus: The Primar ...... other Inflammatory Disorders.

@en

Shifting the Focus: The Primar ...... other Inflammatory Disorders.

@nl

P1476

Shifting the focus - the prima ...... d other inflammatory disorders

@en

P2093

C W Lynde

http://www.w3.org/2001/XMLSchema#string

M J Gooderham

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial

P2860

Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12

Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris

Interleukin-23 drives innate and T cell-mediated intestinal inflammation

A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes

Brodalumab for the Treatment of Psoriasis: A Review of Phase III Trials

The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells

Ustekinumab in treatment of Crohn's disease: design, development, and potential place in therapy

Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

P304

1111-1119

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/JDV.14868

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Kim A. Papp

P5008

ScienceSource

P577

2018-03-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29438576

http://www.w3.org/2001/XMLSchema#string

P921

peptide

psoriasis

P932

6033004

http://www.w3.org/2001/XMLSchema#string